Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18928697 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL22044576 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL19479915 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL20529471 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL29467655 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL20529408 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL20529409 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL29467732 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL24117993 | 0.90 | ALDH1A1 (0.43) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL24118107 | 0.90 | AAK1 (0.47) | ATMALDH1A1GAAGFERAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | disclosed |
| EP-4426741-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | Hangzhou DAC Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| WO-2023078021-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3862023-A1 | CONJUGATES OF CELL-BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou DAC Biotech Co, Ltd (CN) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | ATM 2986/4885MME 2254/4885MMEL1 858/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | ATM 3786/4885MME 2562/4885MMEL1 1849/4885 |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | ATM 2986/4885MME 2254/4885MMEL1 858/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | ATM 4584/4885MME 465/4885MMEL1 193/4885 |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | TEK, TEKT1, EPCAM | ATM 3290/4885MME 553/4885MMEL1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.